TABLE 2.
Microbiological Data of Infections in 92 Children Receiving Intravenous Colistin Therapy
| Overall (n = 92; %) |
Cystic Fibrosis (n = 44; 48%) |
No Cystic Fibrosis (n = 48; 52%) |
P* | |
|---|---|---|---|---|
| Resistance profile of microorganisms identified* | ||||
| Extended-spectrum β-lactamase producer | 5 (5.4) | — | 5 (10.4) | 0.06 |
| Carbapenemase-producing Enterobacteriaceae | 12 (13.0) | 3 (6.8) | 9 (18.8) | 0.12 |
| MDR Achromobacter | 2 (2.2) | 2 (4.5) | — | 0.23 |
| MDR Acinetobacter | 11 (12.0) | 1 (2.3) | 10 (22.7) | <0.01 |
| MDR Pseudomonas | 62 (67.4) | 34 (77.3) | 28 (58.3) | 0.04 |
| MDR Stenotrophomonas | 3 (3.3) | 2 (4.5) | 1 (2.1) | 0.61 |
| Site* | ||||
| Blood | 15 (16.3) | — | 15 (31.3) | <0.01 |
| Cerebrospinal fluid | 1 (1.1) | — | 1 (2.1) | 1 |
| Bone/wound | 5 (5.4) | — | 5 (10.4) | 0.36 |
| Intra-abdominal abscess | 6 (6.5) | — | 6 (12.5) | 0.03 |
| Respiratory tract | 68 (74.1) | 44 (100) | 25 (52.1) | <0.01 |
| Urine | 3 (3.3) | — | 3 (6.3) | 0.24 |
More than 1 response may apply to a patient.
*
Comparing children with and without cystic fibrosis.